2
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The relationship between structural pathology and electrophysiological substrate in cardiac amyloidosis is unclear. Differences between light‐chain ( AL) and transthyretin ( ATTR) cardiac amyloidosis may have prognostic implications.

          Methods and Results

          ECG imaging and cardiac magnetic resonance studies were conducted in 21 cardiac amyloidosis patients (11 AL and 10 ATTR). Healthy volunteers were included as controls. With respect to ATTR, AL patients had lower amyloid volume (51.0/37.7 versus 73.7/16.4 mL, P=0.04), lower myocardial cell volume (42.6/19.1 versus 58.5/17.2 mL, P=0.021), and higher T1 (1172/64 versus 1109/80 ms, P=0.022) and T2 (53.4/2.9 versus 50.0/3.1 ms, P=0.003). ECG imaging revealed differences between cardiac amyloidosis and control patients in virtually all conduction‐repolarization parameters. With respect to ATTR, AL patients had lower epicardial signal amplitude (1.07/0.46 versus 1.83/1.26 mV, P=0.026), greater epicardial signal fractionation ( P=0.019), and slightly higher dispersion of repolarization (187.6/65 versus 158.3/40 ms, P=0.062). No significant difference between AL and ATTR patients was found using the standard 12‐lead ECG. T1 correlated with epicardial signal amplitude (cc=−0.78), and extracellular volume with epicardial signal fractionation (cc=0.48) and repolarization time (cc=0.43). Univariate models based on single features from both cardiac magnetic resonance and ECG imaging classified AL and ATTR patients with an accuracy of 70% to 80%.

          Conclusions

          In this exploratory study cardiac amyloidosis was associated with ventricular conduction and repolarization abnormalities, which were more pronounced in AL than in ATTR. Combined ECG imaging–cardiac magnetic resonance analysis supports the hypothesis that additional mechanisms beyond infiltration may contribute to myocardial damage in AL amyloidosis. Further studies are needed to assess the clinical impact of this approach.

          Related collections

          Most cited references54

          • Record: found
          • Abstract: found
          • Article: found

          Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

          Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal cardiomyopathy for which several promising therapies are in development. The diagnosis is frequently delayed or missed because of the limited specificity of echocardiography and the traditional requirement for histological confirmation. It has long been recognized that technetium-labeled bone scintigraphy tracers can localize to myocardial amyloid deposits, and use of this imaging modality for the diagnosis of cardiac ATTR amyloidosis has lately been revisited. We conducted a multicenter study to ascertain the diagnostic value of bone scintigraphy in this disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Systemic amyloidosis.

            Tissue deposition of protein fibrils causes a group of rare diseases called systemic amyloidoses. This Seminar focuses on changes in their epidemiology, the current approach to diagnosis, and advances in treatment. Systemic light chain (AL) amyloidosis is the most common of these conditions, but wild-type transthyretin cardiac amyloidosis (ATTRwt) is increasingly being diagnosed. Typing of amyloid fibrils, a critical determinant of therapy, has improved with the wide availability of laser capture and mass spectrometry from fixed histological tissue sections. Specific and accurate evaluation of cardiac amyloidosis is now possible using cardiac magnetic resonance imaging and cardiac repurposing of bone scintigraphy tracers. Survival in AL amyloidosis has improved markedly as novel chemotherapy agents have become available, but challenges remain in advanced disease. Early diagnosis, a key to better outcomes, still remains elusive. Broadening the amyloid-specific therapeutic landscape to include RNA inhibitors, fibril formation stabilisers and inhibitors, and immunotherapeutic targeting of amyloid deposits holds promise to transform outcomes in systemic amyloidoses.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy.

              The amyloidoses are a group of protein-folding disorders in which ≥1 organ is infiltrated by proteinaceous deposits known as amyloid. The deposits are derived from 1 of several amyloidogenic precursor proteins, and the prognosis of the disease is determined both by the organ(s) involved and the type of amyloid. Amyloid involvement of the heart (cardiac amyloidosis) carries the worst prognosis of any involved organ, and light-chain (AL) amyloidosis is the most serious form of the disease. The last decade has seen considerable progress in understanding the amyloidoses. In this review, current and novel approaches to the diagnosis and treatment of cardiac amyloidosis are discussed, with particular reference to AL amyloidosis in the heart.
                Bookmark

                Author and article information

                Contributors
                p.lambiase@ucl.ac.uk
                Journal
                J Am Heart Assoc
                J Am Heart Assoc
                10.1002/(ISSN)2047-9980
                JAH3
                ahaoa
                Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
                John Wiley and Sons Inc. (Hoboken )
                2047-9980
                17 September 2019
                09 September 2019
                : 8
                : 18 ( doiID: 10.1002/jah3.v8.18 )
                : e012097
                Affiliations
                [ 1 ] Barts Heart Centre Barts Health NHS Trust London United Kingdom
                [ 2 ] Institute of Cardiovascular Science University College London London United Kingdom
                [ 3 ] The Royal Free Hospital UCL Hospitals Trust London United Kingdom
                [ 4 ] Cardiac Bioelectricity and Arrhythmia Center Washington University in St Louis St. Louis MO
                [ 5 ] MRC London Institute of Medical Sciences Imperial College London London United Kingdom
                Author notes
                [*] [* ] Correspondence to: Pier D. Lambiase, PhD, FRCP, FHRS, Cardiology Department, Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, United Kingdom. E‐mail: p.lambiase@ 123456ucl.ac.uk
                [†]

                Dr Orini and Dr Graham contributed equally to this work as co–first authors.

                [‡]

                Dr Fontana and Dr Lambiase contributed equally to this work as co–senior authors.

                Article
                JAH34397
                10.1161/JAHA.119.012097
                6818012
                31496332
                a593c471-fb4c-44a2-b413-c79565d80948
                © 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 19 January 2019
                : 30 July 2019
                Page count
                Figures: 5, Tables: 4, Pages: 12, Words: 8624
                Funding
                Funded by: British Heart Foundation
                Award ID: FS/18/21/33447
                Funded by: Royal Society
                Award ID: IE141601
                Funded by: NIH
                Award ID: R01‐HL33343
                Funded by: University College London Hospital (UCLH) Biomedicine NIHR
                Funded by: Medtronic
                Funded by: Medical Research Council, UK
                Funded by: Academy of Medical Sciences
                Award ID: SGL015/1006
                Funded by: Imperial College Healthcare NHS Trust
                Funded by: Imperial College London
                Categories
                Original Research
                Original Research
                Imaging
                Custom metadata
                2.0
                jah34397
                17 September 2019
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.7.0 mode:remove_FC converted:23.10.2019

                Cardiovascular Medicine
                amyloid,arrhythmia,electrophysiology mapping,imaging,t1 mapping,electrophysiology,magnetic resonance imaging (mri),electrocardiology (ecg)

                Comments

                Comment on this article